SKYE Skye Bioscience, Inc.
Healthcare$0.83+0.00%OpenMarket Cap: $29.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.65
P/S
0.00
EV/EBITDA
-0.37
DCF Value
$0.10
FCF Yield
-145.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-217.3%
ROA
-295.3%
ROIC
-651.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-12.7M | $-12.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-14.9M | $-14.4M | $— | — |
| FY null | $0.00 | -Infinity% | $-58.2M | $-55.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-13.3M | $-12.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-18.2M | $-17.6M | $— | — |
| Q1 null | $0.00 | NaN% | $-11.8M | $-11.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-10.7M | $-9.7M | $— | — |
| FY null | $0.00 | NaN% | $-30.2M | $-26.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-5.0M | $-3.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-8.4M | $-7.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-6.2M | $-5.0M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-4.1M | $-4.4M | $-0.36 | — |